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Abstract 
Schlager mice (BPH/2J) are hypertensive due to a greater 
contribution of the sympathetic nervous system (SNS) and 
renin angiotensin system (RAS). The kidneys of BPH/2J are 
hyper-innervated suggesting renal nerves may contribute 
to the hypertension. We therefore determined the effect 
of bilateral renal denervation (RD) on hypertension in 
BPH/2J.  
Mean arterial pressure (MAP) was measured by 
radiotelemetry before and for 3 weeks after RD in BPH/2J 
and BPN/3J. The effects of pentolinium and enalaprilat 
were examined to determine the contribution of the SNS 
and RAS respectively. 
After 3 weeks, MAP was -10.9±2.1 mmHg lower in RD 
BPH/2J compared to baseline and -2.1±2.2 mmHg in sham 
BPH/2J (P<0.001, n=8-10). RD had no effect in BPN/3J 
(P>0.1). The depressor response to pentolinium was 
greater in BPH/2J than BPN/3J but in both cases the 
response in RD mice was similar to sham. Enalaprilat 
decreased MAP more in RD BPH/2J compared to sham (-
12 vs -3 mmHg, P<0.001) but had no effect in BPN/3J. RD 
reduced renal noradrenaline in both strains but more so in 
BPH/2J. RD reduced renin mRNA and protein, but not 
plasma renin in BPH/2J to levels comparable with BPN/3J 
mice.  
We conclude that renal nerves contribute to hypertension 
in BPH mice since RD induced a sustained fall in MAP which 
was associated with a reduction of intrarenal renin 
expression. The lack of inhibition of the depressor effects 
of pentolinium and enalaprilat by RD suggests that 
vasoconstrictor effects of the SNS or RAS are not involved. 
These findings support the continued use of RD in the 
treatment of hypertension in humans. 
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INTRODUCTION 
BPH/2J mice are a genetic model of hypertension 
developed by Schlager in the 1970s and selected for their 
elevated blood pressure after crossing 8 normotensive 
strains.1 BPN/3J mice are a normotensive strain obtained 
from the same base population as BPH/2J mice and used 
as their controls. BPH/2J mice are suggested to have a 
neurogenic form of hypertension due to greater activity of 
the sympathetic nervous system (SNS). This was first 
demonstrated when the mean arterial pressure (MAP) of 
BPH/2J mice was reduced by sympathetic ganglion 
blockade to a level similar to that of normotensive BPN/3J 
mice.2 Elevated MAP in BPH/2J mice was associated with 
an increase in central nervous system neuronal activity, 
shown by immunohistochemistry to be 1.7-fold greater in 
the medial amygdala (MeAm) of BPH/2J mice than in 
BPN/3J mice.2 Lesions in the MeAm reduced MAP of 
BPH/2J mice to a level similar to that of the BPN/3J strain, 
confirming the contribution of the MeAm to SNS 
overactivity and the hypertension of BPH/2J mice.3 
Furthermore, BPH/2J mice have greater renal sympathetic 
innervation compared with BPN/3J mice.4 Recently, the 
renin-angiotensin system (RAS) was implicated in the 
hypertension of BPH/2J mice, with evidence that renal 
renin (Ren1) mRNA expression was greater in BPH/2J mice 
compared with BPN/3J mice.4 This increase in renin mRNA 
expression was correlated with a greater depressor 
response to the ganglion inhibitor pentolinium. Thus, we 
hypothesized that exaggerated renal sympathetic activity 
contributes to elevated MAP in BPH/2J mice at least partly 
through a mechanism that includes greater renal renin 
expression. Renal denervation (RD) of BPH/2J mice is 
therefore likely to reduce MAP effectively in this 
neurogenic hypertensive strain. RD is known to reduce 
MAP in a number of other experimental animal models of 
hypertension such as the spontaneously hypertensive rat 
(SHR)5,  DOCA saline hypertension6 but not in Dahl salt 
sensitive hypertension7, mild DOCA salt hypertension,8 or 
Angiotensin II hypertension.9 In patients with resistant 
hypertension, catheter based RD has received much 
attention10, 11 especially more recently with the trial that 
showed its effectiveness in hypertensive patients that had 
Electronic Supplementary material is available at https://static-content.springer.com/esm/art%3A10.1038%2Fs41440-
018-0147-9/MediaObjects/41440_2018_147_MOESM1_ESM.doc 
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been withdrawn from therapy.12 Thus, while there have 
been very many renal denervation studies reported, very 
few have examined the underlying mechanism.  The aim 
of this study was to determine the effects of bilateral RD 
on MAP in BPH/2J and BPN/3J mice. To assess the relative 
contributions of the SNS and RAS in the maintenance of BP 
following RD, pentolinium and the angiotensin-converting 
enzyme (ACE) inhibitor enalaprilat respectively were used.  
Furthermore, the effect of RD on renal renin mRNA and 
protein expression was determined. 
Methods 
Animals 
Experiments were performed on normotensive BPN/3J 
(n=18) and genetically hypertensive BPH/2J (n=12) adult 
male mice with an average age of 14 weeks at the time of 
the first surgery. All experiments were approved by the 
Alfred Medical Research Education Precinct Animal Ethics 
Committee and conducted in accordance with the 
Australian Code of Practice for Scientific Use of Animals. 
Animals were housed individually under conditions of light 
(12 hours on and off) and temperature control with 
environmental enrichment and free access to food and 
water. See on-line data supplement for surgery and 
experimental sequence of events (Figure S1). 
Preliminary Surgery  
Mice underwent 2 surgical procedures under isoflurane 
open circuit anaesthesia (4% induction and 1.5–2% 
maintenance in oxygen; Forthane, Abbott Australasia, 
Botany, NSW, Australia). Carprofen (5 mg/kg, 
subcutaneously, Rimadyl, Pfizer Australia, West Ryde, 
NSW, Australia) and local bupivacaine (2 mg/kg, 
AstraZeneca, North Ryde, NSW, Australia) were given 
before surgery and carprofen was given again 24 hours 
post-surgery for analgesia. In the first operation, a BP 
radiotelemetry transmitter (model TA11PA-C10; Data 
Sciences International, St Paul, MN, USA) was 
implanted.13 The catheter of the telemetry device was 
inserted into the left carotid artery and the transmitter 
was positioned subcutaneously along the right flank. 
Three weeks following telemetry surgery, bilateral RD was 
conducted as described previously.14 Before surgery, 
mice also received atropine (1.2 mg/kg, intraperitoneally, 
Sigma, St Louis, USA) to reduce secretions. Kidneys were 
exposed by an abdominal midline incision. All visible renal 
nerves were cut, renal vessels were stripped, painted with 
a solution of 10% phenol in absolute ethanol and enclosed 
for 3 minutes by a sterile gelatine sponge (1x4mm) soaked 
with the 10% phenol solution. The gelatine sponge was 
removed and surrounding tissue was rinsed with normal 
saline (Baxter Healthcare, Old Toongabbie, NSW, 
Australia). The muscle and skin layers were separately 
sutured, and the mice received Hartmann’s solution (0.3 
mL/mouse, subcutaneously) before being returned to 
their home cages. Sham treated mice underwent surgery 
to expose the kidneys but phenol was not applied. 
Cardiovascular Measurements 
After a 10-day recovery period from telemetry surgery, 
baseline cardiovascular parameters and locomotor activity 
were recorded over 72 hours. Following RD, 
cardiovascular parameters and locomotor activity were 
recorded over 24 hours on 6 occasions within 3 weeks 
(days 3, 6, 9, 12, 18 and 21 post-surgery). All recordings of 
systolic arterial pressure (SAP), diastolic arterial pressure 
(DAP), calculated MAP, heart rate (HR), and locomotor 
activity were obtained in freely moving mice in their home 
cage. The recordings were sampled at 1000 Hz using an 
analogue-to-digital data acquisition card (National 
Instruments 6024E, Austin, Texas, USA).15 The beat-to-
beat data were detected on line and analysed later using 
a program written in the LabVIEW programming language 
(National Instruments, Austin, Texas, USA). 
Cardiovascular Variability and the Cardiac Baroreceptor 
Sensitivity 
Spectral analysis of cardiovascular variability and the 
baroreceptor HR reflex gain were measured during the 
active dark period as described previously in sham and RD 
BPN/3J and BPH/2J mice (n=6-8).3 The auto- and cross-
power spectra were determined for multiple 50% 
overlapping segments of MAP and HR using a Fast Fourier 
transform.  The cardiac baroreflex sensitivity was 
estimated as the average value of the transfer gain in the 
frequency band between 0.3 and 0.5 Hz. Baroreflex slope 
was considered significant if the coherence between MAP 
and HR across several overlapping segments in the 
analysed frequency band was >0.4. Data periods with low 
locomotor activity were chosen (4 from each circadian 
period) from 48-hour recordings minimizing the influence 
of physical activity.  
Assessment of cardiovascular reactivity in response to 
stress tests 
A series of behavioral tests were conducted during the 
inactive period two weeks after RD surgery (days 12-17 
post-surgery) in order to test whether activation of the 
SNS had been affected. Following a 60 min baseline 
recording, animals were exposed to one of three stimuli 
(restraint stress, dirty cage-switch stress and feeding), for 
60 min on three separate days.3 Restraint stress involved 
guiding the mouse into a cylindrical Plexiglas restrainer 
with a sliding back plate to confine the animal. 
Immobilization minimizes the contribution of locomotor 
activity to cardiovascular responses to stress. Dirty cage-
switch stress involved placing the mouse in a cage 
previously occupied by another male mouse. This aversive 
stressor has been demonstrated to induce sustained 
pressor responses as well as increased locomotor 
activity.16 Feeding stress involved presenting palatable 
food (pieces of almond) to mice that had been fasted 
overnight and observing the eating patterns each min 
during the 60 min period.  
Cardiovascular response to ACE inhibition and ganglion 
blockade 
Following a 30 min baseline recording, mice were 
administered the ACE inhibitor enalaprilat (1 mg/kg 
intraperitoneal; Merck & Co, Keniworth, NJ, USA), 
followed 40 minutes later by the ganglion blocker, 
pentolinium (5 mg/kg, intraperitoneal; Sigma-Aldrich, 
Castle Hill, NSW Australia) as described previously.3 ACE 
inhibition prior to ganglion blockade has been shown to 
reduce the compensatory response of the RAS following 
ganglion blockade, unmasking the full contribution of the 
SNS in BPH/2J mice.4 The cardiovascular responses were 
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evaluated during both the light (inactive) period and the 
dark (active) period, on separate days, two weeks after RD 
surgery.  
Tissue and blood collection and analysis 
Three weeks following RD surgery, mice received an 
overdose of sodium pentobarbitone (Lethobarb; Virbac 
Animal Health, New South Wales, Australia) two hours 
after turning off the lights. A blood sample was collected 
by cardiac puncture and plasma and kidneys were snap 
frozen in liquid nitrogen and stored at -80°C. 
Noradrenaline content was later measured in kidneys (n = 
6-10 per group) and results were expressed in pg of 
noradrenaline  per g of wet tissue as previously 
described.17 Renal RNA was extracted and Ren1 mRNA 
abundance was measured in BPH/2J and BPN/3J mouse 
kidneys (n = 7-9 per group), following removal during the 
dark (active) period, as we previously described.4 Data 
from left and right kidneys were averaged. 
Renal protein was extracted from the kidney by the use of 
RIPA buffer (Sigma-Aldrich) and 1% Halt Protease & 
Phosphatase Inhibitor Cocktail (Thermo Scientific, 
Scorseby, Victoria, Australia). Renal protein was quantified 
using DCTM Protein Assay and a bovine serum albumin 
standard (BioRad, Hercules, CA, USA). Mouse plasma 
collected in EDTA tubes (1:10 dilution) and renal protein 
(500 µg) were used to determine Ren1 protein with the 
Mouse Renin1 (Ren1) ELISA kit (Thermo Scientific) 
according to the supplier, in an EnSpire™ Multimode Plate 
Reader (PerkinElmer, Glen Waverley, Victoria Australia). 
Intra-assay coefficients of variability were calculated and 
only those less than 15% variability were accepted. The 
overall variability for the plasma plate was 3% and for the 
renal protein plate 3.8%. 
Data Analysis 
Data were collected over 24-hour periods and were also 
assessed during the 12 hours of lights on (inactive period) 
and lights off (active period). Responses to the different 
stressors were calculated by the difference between the 
60-min baseline period and the 60-min stimulus period. 
The response to enalaprilat was represented by the 
difference between the baseline period (30 min recording 
before treatment) and that recorded 20 to 30 min after 
treatment. To calculate the effect of pentolinium, the 30-
min period following enalaprilat injection was used as the 
control period and compared with the response 10 to 20 
min after pentolinium injection.  
Data are expressed as mean ± SEM and were analysed by 
split plot repeated measures analysis of variance which 
was a mixed model allowing for within-animal and 
between-animal (group) contrasts. Comparisons used 
were Pstrain, which was BPH/2J vs BPN/3J, PRD which was 
sham vs RD and Pbaseline comparing the effect of 
denervation or sham surgery against baseline. Type 1 error 
was controlled using Bonferroni adjustment to the 
probability threshold and Greenhouse-Geisser correction 
to reduce inflated residual degree of freedom.18 A 
probability of P < 0.05 was considered significant. 
Results 
Baseline cardiovascular measurements 
MAP and HR, measured over 24 hours, were 17% and 28% 
higher respectively, in BPH/2J mice compared with BPN/3J 
mice (both Pstrain<0.001, Table 1, baseline pooled from 
sham and RD groups). Locomotor activity was 1.5 fold 
greater in BPH/2J mice (Pstrain=0.02, Table 1). During the 
dark (active) period, MAP and HR in BPH/2J mice were 21% 
and 33% greater, respectively (both Pstrain<0.001), and 
locomotor activity was 1.9 fold greater, (Pstrain<001) than 
in BPN/3J mice (Table 1). A similar pattern was observed 
in MAP and HR during the light (inactive) period but the 
differences between strains were smaller. MAP and HR 
were 13% and 23% greater, respectively, in BPH/2J 
compared to BPN/3J mice (Pstrain< 0.001) but locomotor 
activity was similar in the 2 strains (Pstrain=0.99, Table 1). 
BPN/3J were heavier than BPH/2J mice by 4.1 g (27.9 vs 
23.8g, n=16 and n=18, Pstrain<0.001) which is similar to our 
previous findings.19  
Effects of RD on cardiovascular, locomotor and body 
weight measurements 
After RD, MAP in BPH/2J mice, averaged over 3 weeks, was 
8.5 0.8 mmHg lower than baseline (Pbaseline <0.001) 
compared to sham treated mice in which MAP remained 
similar to baseline (Pbaseline =0.86, Figure 1). The 
reduction was evident by day 3 and remained stable from 
day 6 to the end of the experiment on day 21 (Figure 1). 
There was no detected change from baseline MAP over 
the 3 weeks after sham with the final 3-week reduction 
being 10.9  mmHg lower in RD BPH/2J compared to 
2.1 2.2 mmHg lower in sham BPH/2J.  RD had no effect 
in BPN/3J mice over the 3-week period (Pbaseline >0.1, 
Figure 2). Thus the effect of RD was markedly greater in 
BPH/2J than in BPN/3J mice (Pstrain <0.001).  
HR fell by -38  5 b/min in BPH/2J mice in the 3 weeks 
following RD (Pbaseline <0.001) but was also lower than 
baseline after sham surgery (-31  5 b/min, Pbaseline <0.001, 
Figure 1). In BPN/3J mice, HR was elevated from baseline 
following denervation (+18  5 b/min, Pbaseline=0.027) but 
there was no change following sham surgery (Pbaseline 
=0.42, Figure 2).  
In BPH/2J mice there was a modest reduction in locomotor 
activity level from baseline following RD (Pbaseline=0.011) 
but not sham treatment and there was no effect on 
activity following either sham or RD in BPN/3J mice 
(Pbaseline>0.1).  
There was no difference in the body weight change over 
the 3 weeks in sham or denervated BPN/3J mice 
(Pstrain=0.67, Figure 2). Averaged over the 3 weeks, there 
was a modest decrease in body weight in denervated 
BPH/2J mice particularly between day 3 and 9 that was not 
observed in sham treated mice (Pstrain =0.013, Figure 1). By 
day 21 there was no difference in the body weight 
between the sham or RD BPH/2J mice (Figure 1).  
Effects of RD on circadian pattern of cardiovascular 
measurements 
As the extent of the hypotensive effects of RD were 
relatively constant over the 3 weeks, the average of the 
24-hour recordings of MAP, HR and activity during this 
time were compared to baseline recordings but shown by 
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hourly average to show more clearly the nocturnal pattern 
(Figure 3 and 4). BPH/2J showed markedly higher levels of 
MAP, HR and activity during the active (dark) period 
compared to the inactive (light) period.  By contrast 
BPN/3J exhibited much lesser day night differences in all 
variables.  
We determined whether the changes occurring over the 
three weeks were evident in both the light and dark period 
(Figure 3 and 4).  The hypotensive effect of RD were 
equally evident in BPH/2J mice during both active (dark) 
and inactive (light) periods (Effect between day night 
P=0.40, Figure 3). There was no hypotensive effect of RD 
in BPN/3J mice at 3 weeks compared to baseline and this 
was shown both during the dark and light period (Figure 
3).  Similarly, the maintenance of MAP over the 3-week 
period in sham mice of both strains was evident in both 
the light and dark (Figure 4). By contrast, the HR gradually 
reduced over the 3-week period in BPH/3J.  
Effect of RD on cardiovascular variability and cardiac 
baroreceptor sensitivity 
During the dark (active) period, midfrequency and high 
frequency MAP and HR power were 2-3 fold greater in 
BPH/2J than in BPN/3J mice (Table 2, P<0.05) but 
baroreflex gain were similar between strains (Table 2). 
Low frequency and total MAP and HR power were similar 
in the 2 strains (Table 2). RD had no effect on any 
frequency MAP or HR power in BPN/3J mice and MAP 
power in BPH/2J. However, all frequency of HR power was 
less in BPH/2J RD mice compared to sham (Table 2). Also 
there was a trend for baroreflex gain to be less in RD 
BPH/2J compared to sham (Table 2, P=0.060).  
During the inactive period, only MAP, HR and mid 
frequency HR power were higher in sham BPH/2J 
compared to sham BPN/3J. MAP power, other HR 
frequencies and baroreflex gain were similar between the 
2 strains (Table S1). RD reduced day (inactive) HR in 
BPN/3J but had no other effects on MAP power or HR 
power or baroreflex gain. RD reduced MAP in BPH/2J but 
did not affect other inactive power spectral parameters in 
this strain (Table S1). 
Effects of RD on cardiovascular responses to enalaprilat 
and pentolinium during the active and inactive period 
The acute hypotensive effects of enalaprilat were small 
and only observed in BPH/2J during the active period and 
not in BPN/3J (-3.4 mmHg in BPH/2J vs +3.0 mmHg in 
BPN/3J, Pstrain=0.04, Figure 5). During the active (dark) 
period, treatment with the ACE inhibitor enalaprilat 
following RD in BPH/2J mice induced a greater reduction 
in MAP from baseline compared to the sham procedure (-
11.6 1.8 vs -3.4 1.8 mmHg, respectively, PRD=0.01, 
Figure 5). Conversely, in BPN/3J mice, treatment with 
enalaprilat had no effect on MAP, regardless of whether it 
was after RD or sham surgery (Figure 5). Injection of the 
ganglion blocker pentolinium after enalaprilat treatment 
caused a similar depressor response in RD and sham 
BPH/2J mice (-50±3 and -45±4 mmHg, respectively, Figure 
5) which was also similar in RD and sham BPN/3J mice (-
35±4 vs -28±4 mmHg, respectively, PRD=0.2, Figure 5).  
The depressor response to pentolinium during the active 
was greater in BPH/2J mice compared with BPN/3J mice, 
regardless of whether mice underwent sham or RD 
(Pstrain<0.002). 
During the inactive (light) period, there was a marked 
difference in the effect of enalaprilat administration on 
MAP between the 2 groups of BPH/2J mice, with a fall in 
MAP after RD (-4.2 ± 2.9 mmHg) but a rise in MAP in sham 
treated mice (10 ± 2 mmHg, PRD=0.004, Figure 5). 
Conversely, in BPN/3J mice, enalaprilat had little effect on 
MAP after sham surgery or RD (Figure 5). Pentolinium 
injection after enalaprilat induced similar marked 
depressor responses in both RD and sham BPH/2J mice 
and also similar in RD and sham BPN/3J mice (Figure 5). 
The depressor response to pentolinium during the inactive 
period was greater in BPH/2J mice compared with BPN/3J 
mice, regardless of whether mice underwent sham or RD 
(Pstrain<0.001). 
 
Effects of RD on cardiovascular responses to cage-switch, 
feeding and restraint tests 
RD decreased the hypertensive effect of dirty cage-switch 
in BPH/2J mice by 21 % (PRD<0.001) but had no effect on 
the response in BPN/3J mice (See on-line data supplement 
Figure S2). The tachycardia induced by cage-switch was 
reduced by RD in both BPH/2J and BPN/3J mice 
(PRD<0.05). RD did not alter the elevated locomotor 
activity observed in BPH/2J mice but reduced it in BPN/3J 
mice (P=0.014, Figure S2). 
RD did not affect the cardiovascular responses or 
locomotor activity during the feeding or the restraint test 
in either BPH/2J and BPN/3J mice (See on-line data 
supplement Figures S3 and S4). 
Effects of RD on plasma renin, intrarenal renin and 
intrarenal Ren1 mRNA levels  
Intrarenal renin protein was similar in BPN/3J and BPH/2J 
but reduced in both strains by RD (P<0.05 for both, Figure 
6). By contrast plasma renin levels were similar in both 
strains with intact or denervated renal nerves (Figure 6). 
The expression of Ren1 mRNA was 1.6 fold higher in 
kidneys of sham BPH/2J mice compared to sham BPN/3J 
mice (Pstrain=0.002, Figure 6) and RD abolished the 
difference between strains (Figure 6). The expression of 
PRR mRNA in sham treated mice was ~30% lower in BPH 
(n=8) compared with BPN mice (n=8, P=0.002, Figure 6). 
There was no difference in PRR mRNA abundance in sham 
compared with renal denervated BPN/3J (n=7, P=0.74) or 
BPH/2J mice (n=10, P=0.16). 
Effects of RD on renal noradrenaline levels  
Renal noradrenaline content in the kidneys of sham 
denervated BPH/2J mice was 342 ± 16 pg/g being 1.7 times 
higher than the 200 ± 23 pg/g measured in sham 
denervated BPN/3J mice (Pstrain<0.001). After RD, 
noradrenaline content was 112 ± 15 pg/g in BPH/2J mice 
compared to shams (PRD<0.001) and 99 ± 15 pg/g in 
BPN/3J mice (PRD=0.004). Thus, noradrenaline content of 
the kidney after RD was similar in both strains. In BPH/2J 
there tended to be a correlation between the level of 
noradrenaline in the kidney and the hypotensive effect of 
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RD or sham treatment measured after 3 weeks (r=0.56, 
n=12, P=0.056) but this was not evident in BPN/3J mice 
(See on-line data supplement Figure S5).   
Discussion 
The present study shows that BPH/2J mice have elevated 
renal noradrenaline levels compared with BPN/3J mice, 
providing support for enhanced renal sympathetic activity 
in this hypertensive strain. Importantly, RD resulted in a 
46% reduction in the hypertension over three weeks, 
whereas sham surgery had minimal effect on MAP in 
BPH/2J mice. By contrast, denervation had little effect on 
MAP in BPN/3J mice. Thus, our findings support an 
important role for renal nerves in the hypertension in 
BPH/2J mice. The reduction in MAP in denervated BPH/2J 
mice was not likely due to a reduction in the SNS 
vasomotor tone since the hypotension produced by 
pentolinium was the same in denervated and sham 
BPH/2J. Also, there was not a reduction in the tonic 
vasomotor effects of the RAS as evidenced by the rapid 
effect of ACE inhibitor enalaprilat (within 30 minutes). 
Indeed, the hypotensive effects of enalaprilat actually 
increased after RD in BPH/2J suggesting a partial 
compensatory mechanism rather than the reason for the 
MAP reduction. Interestingly, this occurred without any 
change to plasma renin protein levels. We found that 
there was higher renin mRNA level in the kidney of BPH/2J 
compared to normotensive BPN/3J. The antihypertensive 
effects produced by RD were associated with reductions in 
intrarenal renin protein levels accompanied by lower 
levels of renal renin mRNA compared to sham BPH/2J 
mice. Taken together, these findings support the notion 
that the integrity of renal nerves is important for 
maintaining hypertension in BPH/2J mice and that the 
antihypertensive effects of RD were associated with a 
reduction in renal renin mRNA. These findings are 
consistent with the proposal by Marques and colleagues 
of the important role of intrarenal renin in human 
hypertension 20. 
The reduction in MAP produced by RD was similar during 
the active and inactive phase in BPH/2J suggesting that the 
effect is independent of activity (see Figure 1). It is 
therefore similar to the pattern observed following MeAm 
lesions in this strain, which produced an 11mmHg 
reduction in MAP during both the inactive and active 
phase 3. However, the RAS and the SNS contributions 
were attenuated in the BPH/2J with lesions of the MeAm, 
which contrasts the current study. RD had also very little 
effect on the response to stress. In the present study, RD 
reduced the pressor response to dirty cage-switch stress 
in BPH/2J mice but did not affect the hypertensive 
response to other stressors. Thus, the hypotensive effect 
of RD is not a consequence of attenuated stress reactivity 
involving the SNS. Furthermore, we did not observe any 
significant reduction in the augmented locomotor activity 
associated with BPH/2J mice 19. We also observed a 
reduction in HR but this was similar in both sham and RD 
mice and therefore, unrelated to RD. We have seen a 
similar reduction in HR in BPH/2J over 3 weeks in a 
previous study not involving RD 3. Interestingly there was 
a reduction in baroreflex gain in BPH/2J which was due to 
a reduction in the HR power (at all frequencies) rather 
than a change in fluctuations in MAP (see Table 2) and as 
such reflects less cardiac vagal activity. A small temporary 
reduction in body weight was observed in the RD mice, 
presumably due to loss of fluid related to increased urine 
production which is normally observed after RD 21. Both 
body weight and activity were similar to baseline levels by 
the 3rd week following denervation or sham treatment 
and were not different between groups, suggesting a likely 
specific effect on the cardiovascular system of the RD.  
The reduction in MAP of 8 mmHg which we observed after 
RD in BPH/2J mice was similar to that reported by Hart and 
colleagues in SHR 6-9 days after surgical RD and in human 
subjects 6 months after catheter-based RD 22. Similar 
effects of RD have been shown in other models of 
hypertension including that induced by hyperinsulinemia 
23, DOCA-salt hypertension 24, in offspring from rats with 
reduced uterine perfusion 25, in Dahl salt-sensitive 26, 
SHR 22, 27, 28 and in rats with induced cardio-renal 
syndrome 29. While some studies showed that RD fully 
abolished hypertension, demonstrating similar BP 
between hypertensive and normotensive models after RD 
25, 30, Machino and colleagues reported a 20% reduction 
in systolic BP of SHR 3 months after radiofrequency RD 
without reaching a MAP comparable with normotensive 
rats 28. These findings are in accordance with recent 
studies in humans, in which the blood pressure of 
hypertensive patients did not reach normal values 
following RD 31. However, despite numerous denervation 
studies, few have elucidated the underlying mechanism. 
To assess the contribution of the SNS with and without RD, 
we applied ganglion blockade after ACE inhibition, as this 
reduces the compensatory response of the RAS to the fall 
in MAP, unmasking the full contribution of the SNS 4. We 
assessed the contribution of the SNS and the RAS at the 
end of the experiment but the reduction in MAP we 
observed in BPH/2J was evident within 3 days and 
remained relatively stable over the 3-week period. Our 
observation that the depressor response to ganglion 
blockade with pentolinium was not altered by RD in 
BPH/2J mice, suggests that renal nerve ablation did not 
impact overall SNS related vasomotor activity. This is 
surprising as we have removed sympathetic drive to the 
kidney suggesting that other beds may have compensated 
for the loss of renal vasomotor activity. Similarly, ganglion 
blockade after RD showed little difference to the response 
in BPN/3J mice. We have included spectral analysis in the 
present study as we have previously shown that the mid 
frequency power is greater in BPH/2J compared to BPN/3J 
and that this reflects the augmented sympathetic activity 
in the hypertensive strain 3. In the present study we did 
not observe any difference between the RD and sham 
mice in this frequency which supports the findings with 
ganglionic blockade that SNS activity has not been affected 
by RD. The intact pressor response to restraint stress 
which we have shown to be reliant on the SNS activation 
was well maintained suggesting that the activation of the 
SNS is not near maximal. Nevertheless, the effect of RD 
suggests that the enhanced SNS contribution is 
predominantly in extra-renal beds.  
In the present study, renal catecholamine content was 
higher in BPH/2J mice than their normotensive 
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counterparts, which may be an indicator of greater renal 
SNA in hypertensive mice and provides further support for 
renal sympathetic overactivity being closely associated 
with the hypertension. Renal noradrenaline content in 
SHR, stroke-prone SHR and diabetic rats was similarly 
elevated compared with normotensive controls 28, 32, 33. 
The degree of reduction being 50-70% in the present study 
was more than what is achieved by radiofrequency lesions 
in rats or humans 28, 34, but not as complete as in some 
studies 35. Other studies reported that RD decreased renal 
catecholamines in hypertensive rats to the levels observed 
in normotensive controls 28, 32, 33, 36. Renal 
noradrenaline spillover was also markedly reduced after 
renal nerve ablation in humans 34. However, as previously 
described in other animal models 25, 28, 37, we observed 
that RD also reduced renal noradrenaline in normotensive 
animals without affecting BP. We have previously 
observed a small fall in MAP in normotensive rabbits 
following RD in the order of 6 mmHg and also an enhanced 
depressor response to ganglionic blockade which is unlike 
the effects seen in the present study 38.  
We have previously reported greater renal sympathetic 
innervation in BPH/2J mice as well as enhanced Ren1 
mRNA in the kidney which may be mechanistically 
associated4. In the present study, we found a small but 
significantly greater response to ACE inhibitor enalaprilat 
in sham BPH/2J compared with BPN/3J mice, confirming 
previous findings4 which suggest a greater contribution of 
the RAS to BP maintenance in BPH/2J mice. In sham 
BPH/2J mice, expression of renal renin mRNA was greater, 
whereas PRR mRNA was lower than sham BPN/3J mice but 
there was no difference in plasma renin nor renal protein 
levels between strains in the sham groups. While we found 
that renal renin protein was lower in the denervated 
groups than sham for both BPN and BPH mice, it is 
important to note that renin protein in the kidney closely 
reflects renin storage level whereas, Ren1 mRNA, which 
was only lower in denervated BPH/2J but not BPN/3J mice, 
is more stimulus dependent and thus reflective of the 
state of renin production39. In this study mRNA levels may 
be more informative since we are measuring the effect of 
SNA which dynamically influences renin expression. Since 
sympathetic renal denervation only decrease renal renin 
protein but not mRNA in BPN mice, it is possible that whilst 
denervation has decreased renin stores in BPN mice, they 
have maintained adequate renin production to maintain 
BP. Furthermore, given BPH/2J mice seem to have a far 
greater dependence on RSNA to maintain BP, it is possible 
that BPN mice are more able to compensate for the loss of 
RSNA with other regulatory mechanisms. In the present 
study RD had no effect on either renal PRR or plasma renin 
protein levels in either strain. However, we have not 
measured renin enzyme activity, thus it is possible that 
plasma renin enzyme activity may be elevated in sham 
BPH and may be lowered following denervation. Indeed, 
RD has been shown to reduce plasma renin activity in SHR 
28. 
In conclusion, we suggest that hypertension in BPH/2J 
mice involves overactivity of predominantly the SNS but 
also higher activity intra-renal RAS in the kidney and it is 
the latter mechanism which is responsible for the long-
term antihypertensive effects of RD. These findings 
support the continued use of RD in the treatment of 
hypertension in humans and explain the mechanisms 
involved.   
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Table 1. Sequences of primers and TaqMan probes for mouse GABAA receptor subunits. 
 
Gene   Primer/Probe Sequence  
α1 (assay number Mm00439046) 
 
Forward: 5′-CAA GAG CAG AAG TTG TCT ATG AGT-3′ 
 
Reverse: 5′-GCA CGG CAG ATA TGT TTG AAT AAC-3′ 
 
Probe: 5′-6-FAM-ACC AGA GAG CCA GCC CGT TCA GTG-TAMRA-3′ 
α4 (assay number Mm00802631) 
 
Forward: 5′-AGA ACT CAA AGG ACG AGA AAT TGT -3′ 
 
Reverse: 5′-TTC ACT TCT GTA ACA GGA CCC C -3′ 
 
Probe: 5′-6-FAM-ACG CAG CCT GTT GTC ATA ACC ATC CAG C-TAMRA-3′ 
β2 (assay number Mm00433467) 
 Forward: 5′-AAC TAC ATC TTC TTT GGG AGA GGA -3′ 
 Reverse: 5′-GGT CCA TCT TGT TGA CAT CCA G -3′ 
 Probe: 5′-6-FAM-CGC ATC TTC TCA TTG TTG GCA TTA GCA GC-TAMRA-3′ 
δ (assay number Mm01266203) 
 Forward: 5′-GGA CGT TCT GGG CTG GC -3′ 
 Reverse: 5′-CCT CCA TTA AGC CAT CCA GGT-3′ 
 Probe: 5′-6-FAM-CTG CTG CCG CTC CTG CTG CTC T-TAMRA-3′ 
γ2 (assay number Mm0043349) 
 Forward: 5′-ACT TCT GGT GAC TAT GTG GTG AT -3′ 
 Reverse: 5′-GGC AGG AAC AGC ATC CTT ATT G -3′ 
 Probe: 5′-6-FAM-AAG GAC ACC CAG GAC AGG ACC ACG A-TAMRA-3′ 
GADPH (assay number Mm99999915) 
 
Forward: 5′-CAA TGT GTC CGT CGT GGA TCT -3′ 
 Reverse: 5′-GTC CTC AGT GTA GCC CAA GAT G-3′ 
 Probe: 5′-6-FAM-CGT GCC GCC TGG AGA AAC CTG CC-TAMRA-3′ 
ACTH  (assay number Mm00607939) 
 Forward: 5′-GGC TGC TTT GCT TTC AGT TTT GTA G -3′ 
 Reverse: 5′-CCC AGT TAC TAA GTG GTT TTT TTG CTT G-3′ 
  Probe: 5′-6-FAM-TAC TGA GCT GCG TTT TAC ACC CTT T-TAMRA-3′ 
 
 
Number of neurons labeled for Fos, GABAA receptors and neuropeptide Y (NPY) and the number and percent of 
activated neurons as detected by Fos also labeled for GABAA receptors (Fos + GABAA recs), the number and 
percent of GABAA receptors also containing NPY (GABAA recs + NPY), and the number and percent of activated 
neurons as detected by Fos labeled for GABAA receptors and also containing NPY (Fos + GABAA recs + NPY) in 
the medial amygdala (MeAm) and paraventricular nucleus of the hypothalamus (PVN) of BPN/3J and BPH/2J 
control mice (water only, n=5 per group) and mice treated with diazepam for 7 days (n=6 per group). All mice 
were exposed to 60 min restraint stress. Mean±SEM. *P<0.05, **P<0.01, ***P<0.001 compared with BPN/3J 
mice and ††P<0.01, †††P<0.001 effect of diazepam treatment compared with water control. 
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Table 2: Average 24-hour SAP, DAP, HR and locomotor activity at baseline and weeks 1 and 2 during AlloP or 
vehicle treatment in BPN/3J and BPH/2J mice.   
 
Systolic arterial pressure, SAP; diastolic arterial pressure, DAP; heart rate, HR. Values are mean  SEM. 
Comparison of baseline with weeks 1 and 2 post-minipump implantation with allopregnanolone or vehicle in 
BPN/3J and BPH/2J represented by *P<0.05 and ***P<0.001. Between strain comparison of baseline 
measurements represented by †P<0.05, ††P<0.01 and ††† P< 0.001.  
 
  
Vehicle
P strain
SAP (mmHg) ††† 117 ± 2 120 ± 2 120 ± 2 144 ± 4 149 ± 3 144 ± 3
DAP (mmHg) ††† 88.6 ± 2 89.9 ± 1 89.8 ± 1 109 ± 3 110 ± 3 106 ± 2
MAP (mmHg) ††† 105 ± 2 105 ± 1 105 ± 2 126 ± 3 130 ± 3 125 ± 2
HR (b/min) ††† 480 ± 13 476 ± 11 457 ± 10 572 ± 20 578 ± 20 531 ± 17 *
Activity (units) †† 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.5 ± 0.4 1.8 ± 0.4 1.4 ± 0.3
Allopregnanolone
P strain
SAP (mmHg) ††† 116 ± 2 118 ± 2 120 ± 1 144 ± 3 137 ± 5 132 ± 5 ***
DAP (mmHg) ††† 86.8 ± 1 88.1 ± 2 88.5 ± 1 105 ± 3 102 ± 3 99.2 ± 3 *
MAP (mmHg) ††† 101 ± 1 103 ± 1 104 ± 1 124 ± 3 119 ± 4 115 ± 4 *
HR (b/min) ††† 467 ± 9 491 ± 9 479 ± 8 572 ± 24 584 ± 23 580 ± 23
Activity (units) † 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 1.0 ± 0.2
BPH/2J
Baseline Week 1 Week 2 
Baseline Week 1 Week 2 Week 2 
BPH/2JBPN/3J
BPN/3J
Baseline Week 1 Week 2 
Baseline Week 1
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Figure 1: Effects of allopregnanolone (AlloP) and its vehicle (veh) on mean arterial pressure (MAP). Line graphs 
show hourly averages of MAP during the active (night, outer panels) and inactive (day, middle panel) periods in 
BPN/3J (left, grey n=8-9) and BPH/2J mice (right, black, n=7) at baseline (open symbol) and two weeks following 
minipump implantation (filled symbol). Histograms are mean ± SEM, indicating within animal variance, from 
baseline following one week (unhatched) or two weeks (hatched) treatment with veh (top panels) or AlloP 
(bottom panels) in BPN/3J and BPH/2J mice. Statistical analysis was conducted using multi-factor split-plot 
ANOVA and Bonferroni-adjusted pairwise comparisons both within strains and treatment groups.  Difference 
from baseline * P<0.05.  
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Figure 2 Effects of ganglion blockade. A) Line graphs represent the pooled mean arterial pressure (MAP, mmHg), 
heart rate (HR, beats/min) and activity (Act, units) responses to pentolinium (5 mg/kg) in BPH/2J mice prior to 
(n=6, filled circles) and during treatment with allopregnanolone (n=6, unfilled circles). B) Bar graphs represent 
average changes in MAP, HR and locomotor activity in response to pentolinium in BPN/3J and BPH/2J mice prior 
to (Pre, filled bars) and during treatment with vehicle (Veh, unfilled bars, n=8 for both) and allopregnanolone 
(AlloP, hatched bars, n=6-7). The changes represent the difference between the 30 minute control period and 
the shaded period 10-20 minutes following the injection. Values are mean ± SEM. Statistical analysis was 
conducted using multi-factor split-plot ANOVA and Bonferroni-adjusted pairwise comparisons both within 
strains and treatment groups. NS P>0.05, † P<0.05, †† P<0.01, ††† P<0.001 represent between strain 
comparisons before (Strain Pre) and during allopregnanolone treatment (Strain AlloP). *P<0.05 and ***P<0.001 
represent comparisons within strains before and after minipump implantation.  
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Figure 3 Cardiovascular response to restraint stress before and following treatment with allopregnanolone and 
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its vehicle. Line graphs represent average mean arterial pressure (MAP), heart rate (HR, beats per minute) 
responses before and during restraint stress in BPH/2J mice prior to (n=7, filled circles) and during 
allopregnanolone treatment (n=7, AlloP, unfilled circles). Each circle represents mean ± SEM, averaged across a 
10-minute period.  Bar graphs represent average MAP and HR responses to restraint stress at baseline (pre, filled 
bars) and average response during vehicle (Veh, unfilled bars) or AlloP (hatched bars) treatment in BPN/3J (grey) 
and BPH/2J mice (black). Averages were calculated over 60 minutes of rest and 60 minutes of restraint stress in 
each animal. Values are mean ± SEM. Statistical analysis was conducted using multi-factor split-plot ANOVA and 
Bonferroni-adjusted pairwise comparisons both within strains and treatment groups. †† P<0.01, ††† P<0.001 
represent between strain comparisons prior (Strain Pre) and during AlloP treatment (Strain AlloP).  *P<0.05 and 
***P<0.001 represent comparisons within strains before and after treatment.  
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Figure 4 Cardiovascular response to dirty cage stress before and following treatment with allopregnanolone and its vehicle. 
Line graphs represent average mean arterial pressure (MAP), heart rate (HR, beats per minute) and locomotor activity (Act) 
responses before and during dirty cage switch stress in BPH/2J mice prior to (n=7, black filled circles) and during treatment 
with allopregnanolone (n=7, AlloP, unfilled circles). Each circle represents mean ± SEM, averaged across a 10-minute period.  
Bar graphs represent average MAP, HR and locomotor activity response to the stimuli at baseline (pre, filled bars) and 
average response during vehicle (Veh, unhatched bars, n=7-8) or AlloP (hatched bars, n=7-9) treatment in BPN/3J (grey) and 
BPH/2J (black) mice. Averages were calculated over 60 minutes of rest and 60 minutes of feeding stress in each animal. 
Values are mean ± SEM. Statistical analysis was conducted using multi-factor split-plot ANOVA and Bonferroni-adjusted 
pairwise comparisons both within strains and treatment groups. NS P>0.05, † P<0.05, †† P<0.01, ††† P<0.001 represent 
between strain comparisons before (Strain Pre) and during allopregnanolone treatment (Strain AlloP). ***P<0.001 
represents comparisons within strains before and after minipump implantation.   
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Figure 5 
Cardiovascular response to feeding before and following treatment with allopregnanolone 
and its vehicle. Line graph represent average mean arterial pressure (MAP), heart rate (HR, beats per minute) and 
locomotor activity (Act) responses before and during feeding stress in BPH/2J mice prior to (filled circles) and during 
allopregnanolone treatment (AlloP, unfilled circles, n=6). Each circle represents mean ± SEM, averaged across a 10-minute 
period.  Bar graphs represent average MAP, HR and locomotor activity response to the stimuli at baseline (pre, filled bars) 
and average response during vehicle (Veh, unfilled bars, n=7-8) or AlloP (hatched bars, n=7-9) treatment in BPN/3J and 
BPH/2J mice. Averages were calculated over 60 minutes of rest and 60 minutes of feeding stress in each animal. Values are 
mean ± SEM. Statistical analysis was conducted using multi-factor split-plot ANOVA and Bonferroni-adjusted pairwise 
comparisons both within strains and treatment groups. NS represents between strain comparisons prior (Strain Pre) and 
during AlloP treatment (Strain AlloP).  *P<0.05 represent comparisons before and after treatment. 
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Figure 6  
Fos counts in A) the parvocellular region of the paraventricular nucleus (PVN) of the hypothalamus and B) the 
medial amygdala (MeAm) in hypertensive (BPH, black bars) and normotensive (BPN, grey bars) mice treated 
with allopregnanolone (AlloP, hatched bars) or vehicle (Veh, filled bars). Bars represent mean ± SEM Fos counts. 
* P<0.05 and*** P<0.001 represents comparison between strains and treatment groups using t tests.  
Photomicrographs depict dirty cage switch stress induced Fos expression within the PVN in BPN/3J (1 and 3) and 
BPH/2J (2 and 4) mice treated with vehicle (top panels) or AlloP (bottom panels). Sections were cut coronally 
through the PVN and imaged using a Motic BA400 microscope.  
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Figure 7  
Relative levels of message of GABAA subunits in BPH/2J and BPN/3J mice treated with allopregnanolone and its 
vehicle in the hypothalamus and medial amygdala. Bars represent the mean ± SEM mRNA abundance (2-Δ ΔCT) 
of A) GABAA δ, B) GABAA α4, C) GABAA β2, D) GABAA α1 and E) GABAA γ2 subunits in BPN/3J (grey) and BPH/2J 
(black) mice following two weeks treatment with vehicle (Veh, filled bars) and allopregnanolone (AlloP, hatched 
bars) in the paraventricular nucleus of the hypothalamus. Reference mRNA (ACTB and Gapdh) levels were not 
different between the two groups. * P<0.05, ** P<0.01 *** P<0.001 represents comparison between strains and 
treatment groups using t tests.   
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Supplementary Information 
 
Supplementary Table 1: Average mean arterial pressure, heart rate and power spectral parameters during the inactive (light) period in 
normotensive (BPN/3J) and genetically hypertensive (BPH/2J) mice given either sham or renal denervation (RD). 
 Spectral analysis during the Day (inactive) period         
 BPN Sham BPH Sham BPN Rx BPH Rx 
Sham 
BPN vs 
BPH 
RD 
BPN 
vs 
BPH 
BPN 
Sham vs 
RD 
BPH 
Sham 
vs 
RD 
MAP (mmHg) 94.3 ± 1.8 113.6 ± 1.9 96.1 ± 3.3 104.6 ± 1.5 <0.001 0.06 >0.5 0.04 
HR (beats/min) 313 ± 9 407 ± 9 363 ± 15 405 ± 11 <0.001 0.177 0.08 >0.5 
MAP Power (mmHg)2             
Low Frequency (0.08 - 0.3 Hz) 2.47 ± 0.54 2.41 ± 0.24 2.56 ± 0.45 3.56 ± 0.42 >0.5 0.46 >0.5 0.30 
Mid Frequency (0.3 - 0.5 Hz) 0.81 ± 0.13 1.53 ± 0.19 0.66 ± 0.13 1.5 ± 0.19 0.17 0.14 >0.5 >0.5 
High Frequency (0.5 - 3 Hz) 0.29 ± 0.04 0.38 ± 0.05 0.26 ± 0.04 0.57 ± 0.12 >0.5 0.27 >0.5 >0.5 
Total 5.49 ± 0.94 7.42 ± 0.71 5.77 ± 0.95 9.86 ± 1.03 >0.5 0.16 >0.5 >0.5 
HR power (beats/min)2         
Low Frequency (0.08 - 0.3 Hz) 246.8 ± 42.4 257.1 ± 23.8 158.5 ± 18 255 ± 28.9 >0.5 0.30 0.35 >0.5 
Mid Frequency (0.3 - 0.5 Hz) 170 ± 31.3 409.2 ± 43.7 94.7 ± 13.7 324.1 ± 49.3 0.002 0.01 >0.5 0.39 
High Frequency (0.5 - 3 Hz) 94 ± 12.8 133.4 ± 13.5 59.3 ± 7.3 152.3 ± 29.2 >0.5 0.10 >0.5 >0.5 
Total 971 ± 125 1335 ± 139 639 ± 59 1229 ± 166 >0.5 >0.5 >0.5 >0.5 
         
Coherence (0.3 - 0.5 Hz) 0.63 ± 0.02 0.63 ± 0.01 0.65 ± 0.02 0.64 ± 0.02 >0.5 >0.5 >0.5 >0.5 
Gain (0.5 - 3 Hz) 12.86 ± 0.99 14.45 ± 0.56 11.59 ± 0.8 11.98 ± 0.84 0.48 >0.5 >0.5 0.17 
 
Data are expressed as mean ± SEM and were analysed by split plot analysis of variance. Comparisons were made between Sham BPN (n=7), Sham BPH (n=6), RD BPN (n=5), RD BPH (n=6) groups. 
A probability of P < 0.05 was considered significant. 
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Supplementary Figures 
 
 
Supplementary Figure 1: Diagram for experimental time-course.  
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Supplementary Figure 2: Cardiovascular parameters after the stress test dirty cage-switch. Line graphs show 10-minute 
averages of mean arterial pressure (MAP), heart rate (HR) and locomotor activity over 60 minutes before (control period) and 
during dirty cage-switch in BPN/3J (left, grey circles) and BPH/2J (right, black squares) 2 weeks after renal denervation (RD, closed 
symbol) or sham surgery (open symbol). Histograms are mean change ± SEM from control period in BPN/3J sham mice (Grey 
unfilled, n=8) and BPN/3J RD (grey filled, n=6), BPH/2J sham (black unfilled, n=9), BPH RD (black filled, n=10) and were analysed 
by split plot analysis of variance. A probability of P < 0.05 was considered significant. *P<0.05, **P<0.01, ***P<0.001 for 
comparison of sham treatment with Rx. 
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Supplementary Figure 3: Cardiovascular parameters after feeding test. Line graphs show 10-minute averages of mean arterial 
pressure (MAP), heart rate (HR) and locomotor activity over 60 minutes before (control period) and during feeding in BPN/3J 
(left, grey circles) and BPH/2J (right, black squares) 2 weeks after renal denervation (RD, closed symbol) or sham surgery (open 
symbol). Histograms are mean change ± SEM from control period in BPN/3J sham mice (Grey unfilled, n=8) and BPN/3J RD (grey 
filled, n=4), BPH/2J sham (black unfilled, n=8), BPH RD (black filled, n=10) and were analysed by split plot analysis of variance. A 
probability of P < 0.05 was considered significant.   
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Supplementary Figure 4: Cardiovascular parameters after restrain stress test. Line graphs show 10-minute averages of mean 
arterial pressure (MAP), heart rate (HR) and locomotor activity over 60 minutes before (control period) and during restraint stress 
in BPN/3J (left, grey circles) and BPH/2J (right, black squares) 2 weeks after renal denervation (RD, closed symbol) or sham surgery 
(open symbol). Histograms are mean change ± SEM from control period in BPN/3J sham mice (Grey unfilled, n=8) and BPN/3J RD 
(grey filled, n=7), BPH/2J sham (black unfilled, n=8), BPH RD (black filled, n=10) and were analysed by split plot analysis of variance. 
A probability of P < 0.05 was considered significant. 
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Supplementary Figure 5: Relationship between kidney levels of noradrenaline and the change in mean arterial pressure (MAP 
at day 21) in BPN/3J (top panel, filled circles, n=11) and BPH/2J (lower panel, open circles, n=12). Line represents linear regression. 
R is the correlation co-efficient from a least squares linear regression. A probability of P < 0.05 was considered significant. 
 
 
 
 
